MAP2K7 and melanoma: Roughly 50% of melanoma cases express a BRAF mutation (BRAF-MT) and may either be treated with a BRAF/MEK inhibitor combination or ICI therapy (Figure 2) [114,115,116,117,118,119,120,121,122].